Merus (Netherlands) a preclinical-stage biopharmaceutical focused on antibody product candidates against targets in oncology, inflammation and infectious disease, closed a $30.7M Series B financing. Participants include Novartis Option Fund, Pfizer, Bay City Capital, Life Sciences Partners and Aglaia Biomedical Ventures.

F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.

CeQur (Switzerland) a development-stage device company focused on a wearable insulin infuser for the continuous subcutaneous delivery of insulin for Type II diabetes, closed a $29.6M Series A financing. Participants include BMC Ventures, Endeavour Vision, Schroders and Venture Incubator.

arGEN-X (Netherlands) a development-stage biopharmaceutical company focused on a monoclonal antibody platform with potential indications in autoimmunity, oncology and bone disease, closed a $4.5M Series A financing, bring total round proceeds to $18.3M. Participants have included Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund, [...]

AmVac (Switzerland) a development-stage vaccine company focused on vaginitis , BPH and RSV, closed a $2.8M Series A financing bringing the total round to $4M. Participants include Venture+ and Co Fonds 2.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Morvus Technology (United Kingdom) a preclinical-stage pharmaceutical company focused on prodrug and anti-angiogenic oncology approaches, closed a $3.3M Series A financing. Participants were not identified.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Sinocom Pharmaceutical (China) a commercial-stage manufacturer of active pharmaceutical ingredients for traditional Chinese medicinal pharmaceutical companies, closed a $15M Series A financing. Participants include Seavi Advent Private Equity.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical focused on therapeutic T-cell vaccines for allergies and organ transplant rejection, closed a $25M Series C financing. Participants include Imperial Innovations, Invesco Perpetual and Lansdowne Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $15.2M Series B financing bringing the total round up to $42.3M. Participants include Wellington Partners, Aravis Venture Associates, Auriga Partners and Vinci Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Molecular Partners (Switzerland) a preclinical-stage developing DARPins, a potential new class of protein therapeutics focused on ophthalmology indications, closed a $45M Series B financing. Participants include Essex Woodlands Health Ventures, Index Ventures, Johnson & Johnson Development Corp., BB Biotech Ventures and EndeavourVision.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb